Planning a First-In-Human Clinical Trial?

Unique FIH Solutions
for Small and Large Molecules

Advancing your molecule to first-in-human (FIH) clinical trials is a major milestone. Our FIH solution provides a customized approach that is safe, and delivers quality data with speed and ease.

This eBook provides an overview of how our unique process can facilitate your early-phase clinical program:

    •   small molecule manufacturing experts quickly formulate your drug product and deliver it to the clinical site, ready for dosing;
    •   coordinated processes between our clinic and our bioanalytical labs;
    •   timed interim sample analysis for proactive dose escalation decisions and rapid turnaround of PK/PD analysis between cohorts;
    •   transparent communication between our teams and locations, and strict attention to early-phase timelines; and
    •   a database of over 400,000 normal healthy volunteers and strict safety protocols.

Access the eBook here to learn more.

Speak with one of our experts.

You may also be interested in the following:

Webpages:

    •   Phase I Clinical Trial Units
    •   First-in-Human Trial Capabilities

Scientific Journal:

    •   The Advantages of Conducting Early Phase Clinical Research in Canada